Clinical trials: Vinblastine
Hodgkin Lymphoma
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or…
- Trial name
- NCT01022996
- Testing
- Everolimus (RAD001)
- Where
- 16 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Primary Objectives: Safety of palonosetron administered for control of nausea and vomiting in patients with metastatic melanoma receiving biochemotherapy.
- Trial name
- NCT00412425
- Testing
- Palonosetron
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center